Switzerland-based Carbogen Amcis, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has announced the departure of its current CEO, Pascal Villemagne, and the appointment of his replacement, Stephan Fritschi.

After thirteen years with Carbogen Amcis, the last three of which he served as Chief Executive Officer (CEO), Pascal Villemagne has announced his intent to step down. He will remain in his role until March 31, 2025, and facilitate the handover to the new CEO.

Stephan Fritschi, currently serving as Chief Alliance Officer and deputy CEO, will assume the role of CEO, effective April 1, 2025.

“With more than 25 years at Carbogen Amcis, a perfect knowledge of the company and extensive experience in the pharmaceutical market, Stephan Fritschi brings a deep understanding of the company’s operations, values, and strategic direction, he assures continuity in growing the business,” stated Christian Eich, Chairman of Carbogen Amcis.

“I am honored to take on this role and lead Carbogen Amcis into the future. I look forward to collaborating with the team to continue the progress we have made and to build on the foundations laid by my predecessor, ensuring we continue to deliver value to our customers, employees, and stakeholders,” Stephan Fritschi remarked.